Our second product candidate, MuSK-CAART, targets B cells that give rise to pathogenic autoantibodies against the MuSK receptor in patients with MG.

With an understanding that pathogenic autoantibody epitopes may target any domain of MuSK, multiple MuSK CAAR candidates have been engineered that incorporate all extracellular domains. Each CAAR construct is being or will be tested in preliminary in vitro and in vivo experiments.

The initial in vitro studies with our MuSK-CAART product candidate are ongoing. We expect these studies to be followed by in vivo studies to evaluate toxicity of the MuSK-CAAR construct along with evaluation of target engagement.